Payment overview · 2025
General Payments
$1,501.45
65 reported records · 17 companies
Healthcare provider profile · identity verified
George Peter Silis, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALEXANDRIA, VA · NPI 1003977422
Verified facts
What the public records show
CMS Open Payments records show George Peter Silis, MD received $1,501.45 in general payments during 2025 across 65 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $465.95 | 31.0% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $226.63 | 15.1% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $210.84 | 14.0% | 14 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $87.19 | 5.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.98 | 5.8% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $64.40 | 4.3% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.31 | 3.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.47 | 3.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $50.01 | 3.3% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $36.44 | 2.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $30.90 | 2.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.10 | 2.0% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.91 | 1.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $26.85 | 1.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.94 | 1.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $15.30 | 1.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.23 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,501.45 | 65 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $283.99 | 6 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $149.19 | 7 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $149.19 | 7 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $149.19 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $147.38 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $97.89 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $97.89 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $97.34 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $93.75 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $87.19 | 4 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $64.40 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $61.59 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $60.38 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.38 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.77 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $39.29 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.47 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $30.90 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $30.10 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $28.98 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $26.60 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.36 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.03 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 213 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 361 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 316 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 293 | 92 |
| Eliquis | Apixaban | 213 | 34 |
| Levothyroxine Sodium | Levothyroxine Sodium | 208 | 52 |
| Losartan Potassium | Losartan Potassium | 195 | 58 |
| Metformin Hcl | Metformin Hcl | 172 | 51 |
| Montelukast Sodium | Montelukast Sodium | 164 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 149 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 35 |
| Lisinopril | Lisinopril | 145 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 142 | 48 |
| Famotidine | Famotidine | 134 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 24 |
| Simvastatin | Simvastatin | 85 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 82 | 23 |
| Furosemide | Furosemide | 79 | 23 |
| Prednisone | Prednisone | 78 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 19 |
| Finasteride | Finasteride | 72 | 19 |
| Potassium Chloride | Potassium Chloride | 70 | 27 |
| Alprazolam | Alprazolam | 68 | 13 |
| Jardiance | Empagliflozin | 67 | 15 |
| Gabapentin | Gabapentin | 64 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 61 | suppressed |
| Carvedilol | Carvedilol | 60 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 21 |
| Trazodone Hcl | Trazodone Hcl | 59 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 18 |
| Azithromycin | Azithromycin | 55 | 45 |
| Allopurinol | Allopurinol | 52 | 16 |
| Ezetimibe | Ezetimibe | 49 | 13 |
| Sertraline Hcl | Sertraline Hcl | 49 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | 13 |
| Lorazepam | Lorazepam | 48 | 14 |
| Valsartan | Valsartan | 46 | 19 |
| Donepezil Hcl | Donepezil Hcl | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Glimepiride | Glimepiride | 40 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Omeprazole | Omeprazole | 38 | 13 |
| Cefuroxime | Cefuroxime Axetil | 37 | 28 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Nystatin | Nystatin | 29 | 16 |
| Spironolactone | Spironolactone | 29 | 13 |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | 11 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 18 |
| Fluconazole | Fluconazole | 25 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 20 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Erythromycin | Erythromycin Base | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,501.45 · 65 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, INGREZZA, INSPIRE, JARDIANCE, KRYSTEXXA, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error